| Literature DB >> 27901497 |
Yong Xu1, Ning Hu2, Wei Jiang1, Hong-Fang Yuan3, Dong-Hui Zheng1.
Abstract
Renal ischemia-reperfusion injury (IRI) is a major complication in clinical practice. However, despite its frequency, effective preventive/treatment strategies for this condition are scarce. Curcumin possesses antioxidant properties and is a promising potential protective agent against renal IRI, but its poor water solubility restricts its application. In this study, we constructed curcumin-carrying distearoylphosphatidylethanolamine-polyethylene glycol nanoparticles (Cur-NPs), and their effect on HK-2 cells exposed to IRI was examined in vitro. Curcumin encapsulated in NPs demonstrated improved water solubility and slowed release. Compared with the IRI and Curcumin groups, Cur-NP groups displayed significantly improved cell viability, downregulated protein expression levels of caspase-3 and Bax, upregulated expression of Bcl-2 protein, increased antioxidant superoxide dismutase level, and reduced apoptotic rate, reactive oxygen species level, and malondialdehyde content. Results clearly showed that Cur-NPs demonstrated good water solubility and slow release, as well as exerted protective effects against oxidative stress in cultured HK-2 cells exposed to IRI.Entities:
Keywords: Curcumin; ischemia-reperfusion injury; nanoparticles
Mesh:
Substances:
Year: 2016 PMID: 27901497 PMCID: PMC5349996 DOI: 10.18632/oncotarget.13626
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1The solution of Cur-NPs in test tube
A. Non-encapsulated curcumin B. Blank nanoparticles C. Cur-NPs.
Figure 2Size and Zeta potential of DSPE-PEG nanoparticles
Figure 3Release curve of Curcumin drug-loading nanoparticles and bare curcumin medicine in vitro
Figure 4Detection of cell proliferation determined by MTT method
Figure 5The change of apoptosis detected flow cytometry
A. Normal control group. B. IRI group. C. IRI+Cur group. D. IRI+Cur-NPs group.
Figure 6The results of DAPI staining after hypoxia reoxygenation at 24h
A. Normal control group; B. IRI group; C. IRI+Cur group; D. IRI+Cur-NPs group.
Figure 7MDA and SOD tests
Figure 8Changes in Expression levels of caspase-3, Bax, and Bcl-2 proteins in each group